Lipum AB (publ) (LIPUM.ST)
SEK 13.3
(-1.48%)
SEK 13.3
(-1.48%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 37.3 Million SEK | -1.32% |
| 2022 | 37.8 Million SEK | -29.3% |
| 2021 | 53.47 Million SEK | 153.77% |
| 2020 | 21.07 Million SEK | 125.25% |
| 2019 | 9.35 Million SEK | 1817164.11% |
| 2018 | 514.80 SEK | 53.52% |
| 2017 | 335.33 SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 9.27 Million SEK | 29.64% |
| 2024 Q3 | 1.63 Million SEK | -91.26% |
| 2024 Q2 | 18.68 Million SEK | 101.34% |
| 2023 Q2 | 14 Million SEK | 96.07% |
| 2023 FY | 32.58 Million SEK | -13.81% |
| 2023 Q4 | 7.15 Million SEK | 22.11% |
| 2023 Q3 | 5.86 Million SEK | -58.16% |
| 2023 Q1 | 7.14 Million SEK | -44.14% |
| 2022 Q3 | 9.88 Million SEK | 6.03% |
| 2022 Q1 | 5.81 Million SEK | -80.9% |
| 2022 FY | 37.8 Million SEK | -29.3% |
| 2022 Q2 | 9.32 Million SEK | 60.28% |
| 2022 Q4 | 12.78 Million SEK | 29.42% |
| 2021 FY | 53.47 Million SEK | 153.77% |
| 2021 Q4 | 30.44 Million SEK | 442.91% |
| 2021 Q3 | 5.6 Million SEK | -50.53% |
| 2021 Q2 | 11.33 Million SEK | 85.99% |
| 2021 Q1 | 6.09 Million SEK | -37.33% |
| 2020 FY | 21.07 Million SEK | 125.25% |
| 2020 Q4 | 9.72 Million SEK | 1048.75% |
| 2020 Q3 | -1.02 Million SEK | 0.0% |
| 2019 FY | 9.35 Million SEK | 1817164.11% |
| 2018 FY | 514.80 SEK | 53.52% |
| 2017 FY | 335.33 SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 87.851% |
| Ziccum AB (publ) | 27.87 Million SEK | -33.822% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | -127.468% |
| BioArctic AB (publ) | 89.62 Million SEK | 58.375% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 12.491% |
| Mendus AB (publ) | 129.13 Million SEK | 71.111% |
| Genovis AB (publ.) | 88.19 Million SEK | 57.7% |
| Intervacc AB (publ) | 79.78 Million SEK | 53.241% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | -110.977% |
| Active Biotech AB (publ) | 44.8 Million SEK | 16.742% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 72.551% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 55.143% |
| Aptahem AB (publ) | 10.01 Million SEK | -272.588% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 88.396% |
| Kancera AB (publ) | 63.07 Million SEK | 40.855% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 72.302% |
| Fluicell AB (publ) | 28.61 Million SEK | -30.367% |
| Saniona AB (publ) | 1.07 Million SEK | -3363.974% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -414.296% |
| Biovica International AB (publ) | 133.72 Million SEK | 72.101% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | -88.514% |
| AcouSort AB (publ) | 25.87 Million SEK | -44.176% |
| Xintela AB (publ) | 57.31 Million SEK | 34.91% |
| Abliva AB (publ) | 27.86 Million SEK | -33.88% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 80.72% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -575.974% |
| OncoZenge AB (publ) | 15.9 Million SEK | -134.561% |
| Amniotics AB (publ) | 29.07 Million SEK | -28.326% |
| 2cureX AB (publ) | 36.51 Million SEK | -2.161% |
| CombiGene AB (publ) | 44.14 Million SEK | 15.488% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -154.603% |
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 97.536% |
| Camurus AB (publ) | 1.05 Billion SEK | 96.479% |
| Corline Biomedical AB | 30.16 Million SEK | -23.664% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 35.712% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -413.305% |
| I-Tech AB | 40.14 Million SEK | 7.076% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 95.659% |
| Cyxone AB (publ) | 28.21 Million SEK | -32.229% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 65.889% |
| Biosergen AB | 26.8 Million SEK | -39.158% |
| Cantargia AB (publ) | 290.01 Million SEK | 87.136% |
| NextCell Pharma AB | -576.01 Thousand SEK | 6576.696% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 79.472% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | -31.704% |
| Nanologica AB (publ) | 69.88 Million SEK | 46.618% |
| SynAct Pharma AB | 224.49 Million SEK | 83.382% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 15.549% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | -55.743% |
| LIDDS AB (publ) | 27.75 Million SEK | -34.43% |
| BioInvent International AB (publ) | 441.4 Million SEK | 91.548% |
| Alzinova AB (publ) | 36.39 Million SEK | -2.503% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 87.124% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -374.869% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 67.58% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | -70.391% |
| Simris Alg AB (publ) | 38.64 Million SEK | 3.455% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 73.909% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 89.568% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 66.364% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -153.789% |